Updating results

794 results

Sort: Relevance | Date

Cellulitis and erysipelas – antimicrobial prescribing

Everything NICE has said on antimicrobial prescribing for cellulitis and erysipelas in an interactive flowchart

NICE Pathway Published September 2019

Osteoarthritis

Everything NICE has said on the care and management of osteoarthritis in adults in an interactive flowchart

NICE Pathway Published February 2014 Last updated October 2019

Blood and immune system conditions

Everything NICE has said on blood and immune system conditions in an interactive flowchart

NICE Pathway Published November 2014 Last updated October 2019

Postnatal care

Everything NICE has said on the essential care that every woman and her baby should receive in the first 6–8 weeks after birth in an interactive flowchart

NICE Pathway Published May 2011 Last updated November 2019

Abortion care

Everything NICE has said on abortion care in an interactive flowchart.

NICE Pathway Published September 2019 Last updated February 2020

Myocardial infarction with ST-segment elevation

Everything NICE has said on the acute management of myocardial infarction with ST-segment elevation in an interactive flowchart

NICE Pathway Published July 2013 Last updated January 2020

Aortic aneurysms

Everything NICE has said on aortic aneurysms in an interactive flowchart

NICE Pathway Published March 2014 Last updated January 2020

Non-Hodgkin's lymphoma

Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

NICE Pathway Published July 2016 Last updated October 2019

Respiratory conditions

Everything NICE has said on respiratory conditions in an interactive flowchart

NICE Pathway Published June 2015 Last updated October 2019

Generalised anxiety disorder

Everything NICE has said on managing generalised anxiety disorder in adults in primary, secondary and community care in an interactive flowchart

NICE Pathway Published March 2012 Last updated October 2019

Urogenital conditions

Everything NICE has said on urogenital conditions in an interactive flowchart

NICE Pathway Published June 2015 Last updated November 2019

End of life care for people with life-limiting conditions

Everything NICE has said about the care of people with a progressive life-limiting condition who are at the end of their life in an interactive flowchart

NICE Pathway Published March 2017 Last updated October 2019

Bronchiectasis (non-cystic fibrosis) – antimicrobial prescribing

Everything NICE has said on antimicrobial prescribing for managing and preventing an acute exacerbation of bronchiectasis (non-cystic fibrosis) in an interactive flowchart

NICE Pathway Published December 2018 Last updated September 2019

Sepsis

Everything NICE has said on the recognition, diagnosis and early management of sepsis in an interactive flowchart

NICE Pathway Published July 2016 Last updated February 2020

Pneumonia

Everything NICE has said on diagnosing and managing community- and hospital-acquired pneumonia in an interactive flowchart

NICE Pathway Published December 2014 Last updated February 2020

Neutropenic sepsis

Everything NICE has said on preventing, identifying and managing neutropenic sepsis in children, young people and adults in an interactive flowchart

NICE Pathway Published September 2012 Last updated February 2020

Multiple sclerosis

Everything NICE has said on multiple sclerosis in an interactive flowchart

NICE Pathway Published October 2014 Last updated February 2020

Antimicrobial stewardship

Everything NICE has said on effective antimicrobial medicine use and preventing the spread of resistant microbes in an interactive flowchart

NICE Pathway Published August 2015 Last updated February 2020

Depression

Everything NICE has said on identifying, treating and managing depression in children, young people and adults in an interactive flowchart

NICE Pathway Published May 2011 Last updated February 2020

Multiple pregnancy: twin and triplet pregnancies (QS46)

This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.

Quality standard Published September 2013 Last updated September 2019

Lung cancer in adults (QS17)

This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.

Quality standard Published March 2012 Last updated December 2019

Rheumatoid arthritis in over 16s (QS33)

This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.

Quality standard Published June 2013 Last updated January 2020

Colorectal cancer (QS20)

This quality standard covers managing colorectal (bowel) cancer in adults (aged 18 and over). It includes managing local disease and secondary tumours (metastatic disease). It describes high-quality care in priority areas for improvement.

Quality standard Published August 2012 Last updated January 2020

Suicide prevention (QS189)

This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.

Quality standard Published September 2019

Coexisting severe mental illness and substance misuse (QS188)

This quality standard covers the assessment, management and care provided for people aged 14 and over who have coexisting severe mental illness and substance misuse. It describes high-quality care in priority areas for improvement.

Quality standard Published August 2019

Flu vaccination: increasing uptake (QS190)

This quality standard covers increasing the uptake of flu vaccination among people who are eligible. It describes high-quality care in priority areas for improvement.

Quality standard Published January 2020

Cerebral palsy in adults (QS191)

This quality standard covers care and support for adults with cerebral palsy (aged 25 and over). It describes high-quality care in priority areas for improvement.

Quality standard Published January 2020

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

Highly specialised technologies guidance Published November 2019

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

Highly specialised technologies guidance Published October 2019

Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) (TA618)

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC

Technology appraisal guidance Published January 2020

Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)

NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib

Technology appraisal guidance Published October 2019

Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults

Technology appraisal guidance Published October 2019

Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA603)

NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma

Technology appraisal guidance Published September 2019

Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA602)

NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma

Technology appraisal guidance Published September 2019

Bezlotoxumab for preventing recurrent Clostridium difficile infection (terminated appraisal) (TA601)

NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults

Technology appraisal guidance Published September 2019

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published August 2019

Dapagliflozin with insulin for treating type 1 diabetes (TA597)

Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a

Technology appraisal guidance Published August 2019 Last updated February 2020

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer that

Technology appraisal guidance Published August 2019

Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults

Technology appraisal guidance Published September 2019

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)

Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung

Technology appraisal guidance Published September 2019

Idelalisib for treating refractory follicular lymphoma (TA604)

Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults

Technology appraisal guidance Published October 2019

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) in adults

Technology appraisal guidance Published October 2019

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

Technology appraisal guidance Published October 2019

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease

Technology appraisal guidance Published October 2019

Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults

Technology appraisal guidance Published November 2019

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

Evidence-based recommendations on rucaparib (Rubraca) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer that has responded to

Technology appraisal guidance Published November 2019

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA621)

Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published January 2020

Sotagliflozin with insulin for treating type 1 diabetes (TA622)

Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2

Technology appraisal guidance Published February 2020

Patiromer for treating hyperkalaemia (TA623)

Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults

Technology appraisal guidance Published February 2020

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults

Technology appraisal guidance Published February 2020